Literature DB >> 12902889

Pulmonary metastases tumor doubling time: assessment by computed tomography.

Rubens Chojniak1, Riad N Younes.   

Abstract

Growth rate is a prognostic factor for pulmonary metastases treatment. We used computed tomography (CT) to quantify tumor doubling time (Tdt) variation of pulmonary metastases in the same patient, from different histologies and sizes. We prospectively evaluated chest CTs of patients with pulmonary metastases under no cancer treatment. Tdt of 408 pulmonary nodules in 21 patients was determined. One hundred twenty-three (30%) remained unaltered, 44 (11%) had reduction, and 241 (59%) increased in size. Nodules that grew presented a mean Tdt of 118 +/- 134 days (range: 22-930 days). There was high intraindividual variability of mean Tdt with no difference between histologies. Smaller nodules presented greater tendency to grow, and lower Tdt. There is large variation in clinical behavior for pulmonary metastases in the same patient. Each nodule should be evaluated independently. Selection of a single nodule to evaluate metastatic disease behavior could influence the therapeutic decision.

Entities:  

Mesh:

Year:  2003        PMID: 12902889     DOI: 10.1097/01.COC.0000026481.38654.52

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  7 in total

1.  Imprecision in automated volume measurements of pulmonary nodules and its effect on the level of uncertainty in volume doubling time estimation.

Authors:  Paul J Nietert; James G Ravenel; William M Leue; James V Miller; Katherine K Taylor; Elizabeth S Garrett-Mayer; Gerard A Silvestri
Journal:  Chest       Date:  2009-01-13       Impact factor: 9.410

2.  The prognostic value of positron emission tomography/computed tomography in pulmonary metastasectomy.

Authors:  Satoshi Shiono; Makoto Endo; Katsuyuki Suzuki; Kei Yarimizu; Kazuki Hayasaka
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

3.  Response to chemotherapy in patients with lung metastases: how many nodules should be measured?

Authors:  R Chojniak; L S Yu; R N Younes
Journal:  Cancer Imaging       Date:  2006-07-13       Impact factor: 3.909

Review 4.  Functional imaging biomarkers for assessing response to treatment in liver and lung metastases.

Authors:  Livia Bernardin; Elizabeth A M O'Flynn; Nandita M Desouza
Journal:  Cancer Imaging       Date:  2013-12-11       Impact factor: 3.909

Review 5.  Chronology of gastrointestinal cancer.

Authors:  Kentaro Murakami; Hisahiro Matsubara
Journal:  Surg Today       Date:  2017-08-09       Impact factor: 2.549

6.  Automated CT volumetry of pulmonary metastases: the effect of a reduced growth threshold and target lesion number on the reliability of therapy response assessment using RECIST criteria.

Authors:  Katharina Marten; Florian Auer; Stefan Schmidt; Ernst J Rummeny; Christoph Engelke
Journal:  Eur Radiol       Date:  2007-05-10       Impact factor: 7.034

7.  A mammary adenocarcinoma murine model suitable for the study of cancer immunoediting.

Authors:  Lucas Pagura; Juan Manuel Cáceres; Albertina Cardinale; Olga Graciela Scharovsky; Ricardo José Di Masso; Mariano Federico Zacarías-Fluck; María José Rico; Viviana Rosa Rozados
Journal:  J Biomed Sci       Date:  2014-05-30       Impact factor: 8.410

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.